|
市場調査レポート
商品コード
1746515
日本のコンパニオン診断市場レポート：製品・サービス、技術、適応症、エンドユーザー、地域別、2025～2033年Japan Companion Diagnostics Market Report by Product & Service, Technology (Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing, and Others), Indication, End User, and Region 2025-2033 |
||||||
カスタマイズ可能
|
|||||||
| 日本のコンパニオン診断市場レポート：製品・サービス、技術、適応症、エンドユーザー、地域別、2025～2033年 |
|
出版日: 2025年06月02日
発行: IMARC
ページ情報: 英文 122 Pages
納期: 5～7営業日
|
- 全表示
- 概要
- 目次
日本のコンパニオン診断市場規模は2024年に4億4,950万米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに12億850万米ドルに達し、2025～2033年にかけて11.60%の成長率（CAGR）を示すと予測しています。がん罹患率の上昇、個別化医療のニーズの高まり、次世代シーケンス（NGS）のような継続的な技術進歩が、市場成長を促進する主要因の1つです。
本レポートで扱う主要質問
- 日本のコンパニオン診断市場はこれまでどのように推移し、今後どのように推移するのか？
- COVID-19が日本のコンパニオン診断市場に与えた影響は？
- 日本のコンパニオン診断市場の製品・サービス別区分は？
- 日本のコンパニオン診断市場の技術別区分は？
- 日本のコンパニオン診断市場の適応症別区分は？
- 日本のコンパニオン診断市場のエンドユーザー別区分は？
- 日本のコンパニオン診断市場のバリューチェーンにおける様々なステージとは？
- 日本のコンパニオン診断の主要な促進要因と課題は何か？
- 日本のコンパニオン診断市場の構造と主要参入企業は？
- 日本のコンパニオン診断市場における競合の程度は？
目次
第1章 序文
第2章 調査範囲と調査手法
- 調査の目的
- ステークホルダー
- データソース
- 市場推定
- 調査手法
第3章 エグゼクティブサマリー
第4章 日本のコンパニオン診断市場-イントロダクション
- 概要
- 市場力学
- 産業動向
- 競合情報
第5章 日本のコンパニオン診断市場情勢
- 過去と現在の市場動向（2019～2024年）
- 市場予測（2025～2033年）
第6章 日本のコンパニオン診断市場-製品・サービス別内訳
- アッセイ、キット、試薬
- ソフトウェアとサービス
第7章 日本のコンパニオン診断市場-技術別内訳
- 免疫組織化学（IHC）
- ポリメラーゼ連鎖反応（PCR）
- in situーハイブリダイゼーション（ISH）
- リアルタイムPCR（RT-PCR）
- 遺伝子配列分析
- その他
第8章 日本のコンパニオン診断市場-適応症別内訳
- がん
- 神経疾患
- 感染症
- 心血管疾患
- その他
第9章 日本のコンパニオン診断市場-エンドユーザー別内訳
- 製薬・バイオ医薬品企業
- リファレンスラボ
- 契約研究機関
- その他
第10章 日本のコンパニオン診断市場-競合情勢
- 概要
- 市場構造
- 市場企業のポジショニング
- 主要成功戦略
- 競合ダッシュボード
- 企業評価象限
第11章 主要企業のプロファイル
第12章 日本のコンパニオン診断市場-産業分析
- 促進要因・抑制要因・機会
- ポーターのファイブフォース分析
- バリューチェーン分析
第13章 付録
Japan companion diagnostics market size reached USD 449.5 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,208.5 Million by 2033, exhibiting a growth rate (CAGR) of 11.60% during 2025-2033. The rising incidence of cancer, the growing need for personalized medicine, and continuous technological advancements like next-generation sequencing (NGS), are among the primary factors propelling the market growth.
Companion diagnostics refer to medical tests that aid physicians in identifying the most suitable treatment strategy. They are crafted to detect specific biomarkers present in a patient's tissue or blood sample, indicating whether the patient is likely to respond positively to a particular drug or therapeutic approach. Additionally, they delve into the intricate biological profile and mechanism of action (MOA) of patients, assisting healthcare professionals in comprehending potential medication side effects. The widespread application of companion diagnostics is evident in personalized medicine, where it takes into account the distinct characteristics of each patient, such as their genetic composition, to determine the optimal treatment course. Beyond this, there is a growing use of companion diagnostics for examining specific genetic mutations in cancer patients or identifying biomarkers in those with hepatitis C.
Japan Companion Diagnostics Market Trends:
The Japan companion diagnostics market is experiencing significant growth, primarily propelled by the increasing incidence of diverse cancer types, which is fostering the demand for more precise and targeted cancer treatments. Additionally, the escalating demand for personalized medicines, tailored to the unique characteristics of each patient, further contributes to the optimistic market outlook. Simultaneously, the widespread adoption of targeted drugs and therapies addressing various infectious, cardiovascular, neurological, and inflammatory conditions serves as another substantial growth driver. The regulatory landscape for companion diagnostics in Japan is favorable, with an increasing number of tests receiving approvals. This, coupled with the expanding number of global clinical trials, strengthens the market growth. Ongoing advancements in diagnostic technologies, such as the emergence of next-generation sequencing (NGS) and liquid biopsy, are pivotal, enabling the identification of previously challenging-to-detect biomarkers. The development of innovative genomic technologies plays a key role, facilitating the identification of genetic mutations and biomarkers crucial for guiding treatment decisions, thereby fueling market growth. Additionally, factors like the growing use of biomarkers in drug development, substantial investments in precision medicine, and heightened consumer awareness regarding the benefits of companion diagnostics are projected to present lucrative growth opportunities for the regional market over the forecasted period.
Japan Companion Diagnostics Market Segmentation:
Product & Service Insights:
- Assays, Kits and Reagents
- Software and Services
Technology Insights:
- Immunohistochemistry (IHC)
- Polymerase Chain Reaction (PCR)
- In-situ Hybridization (ISH)
- Real-time PCR (RT-PCR)
- Gene Sequencing
- Others
Indication Insights:
- Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Melanoma
- Others
- Neurological Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Others
End User Insights:
- Pharmaceutical & Biopharmaceutical Companies
- Reference Laboratories
- Contract Research Organizations
- Others
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Key Questions Answered in This Report:
- How has the Japan companion diagnostics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the Japan companion diagnostics market?
- What is the breakup of the Japan companion diagnostics market on the basis of product & service?
- What is the breakup of the Japan companion diagnostics market on the basis of technology?
- What is the breakup of the Japan companion diagnostics market on the basis of indication?
- What is the breakup of the Japan companion diagnostics market on the basis of end user?
- What are the various stages in the value chain of the Japan companion diagnostics market?
- What are the key driving factors and challenges in the Japan companion diagnostics?
- What is the structure of the Japan companion diagnostics market and who are the key players?
- What is the degree of competition in the Japan companion diagnostics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Japan Companion Diagnostics Market - Introduction
- 4.1 Overview
- 4.2 Market Dynamics
- 4.3 Industry Trends
- 4.4 Competitive Intelligence
5 Japan Companion Diagnostics Market Landscape
- 5.1 Historical and Current Market Trends (2019-2024)
- 5.2 Market Forecast (2025-2033)
6 Japan Companion Diagnostics Market - Breakup by Product & Service
- 6.1 Assays, Kits and Reagents
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
- 6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
7 Japan Companion Diagnostics Market - Breakup by Technology
- 7.1 Immunohistochemistry (IHC)
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
- 7.2 Polymerase Chain Reaction (PCR)
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
- 7.3 In-situ Hybridization (ISH)
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
- 7.4 Real-time PCR (RT-PCR)
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
- 7.5 Gene Sequencing
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
- 7.6 Others
- 7.6.1 Historical and Current Market Trends (2019-2024)
- 7.6.2 Market Forecast (2025-2033)
8 Japan Companion Diagnostics Market - Breakup by Indication
- 8.1 Cancer
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Segmentation
- 8.1.3.1 Lung Cancer
- 8.1.3.2 Breast Cancer
- 8.1.3.3 Colorectal Cancer
- 8.1.3.4 Gastric Cancer
- 8.1.3.5 Melanoma
- 8.1.3.6 Others
- 8.1.4 Market Forecast (2025-2033)
- 8.2 Neurological Diseases
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
- 8.3 Infectious Diseases
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
- 8.4 Cardiovascular Diseases
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
- 8.5 Others
- 8.5.1 Historical and Current Market Trends (2019-2024)
- 8.5.2 Market Forecast (2025-2033)
9 Japan Companion Diagnostics Market - Breakup by End User
- 9.1 Pharmaceutical & Biopharmaceutical Companies
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
- 9.2 Reference Laboratories
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
- 9.3 Contract Research Organizations
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
- 9.4 Others
- 9.4.1 Historical and Current Market Trends (2019-2024)
- 9.4.2 Market Forecast (2025-2033)
10 Japan Companion Diagnostics Market - Competitive Landscape
- 10.1 Overview
- 10.2 Market Structure
- 10.3 Market Player Positioning
- 10.4 Top Winning Strategies
- 10.5 Competitive Dashboard
- 10.6 Company Evaluation Quadrant
11 Profiles of Key Players
- 11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
- 11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
- 11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
- 11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
- 11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events
12 Japan Companion Diagnostics Market - Industry Analysis
- 12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
- 12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
- 12.3 Value Chain Analysis
